Briefs: Biocon, Laurus Labs and Smruthi Organics
Laurus Labs has announced that the USFDA completed inspection of the formulations manufacturing facility Unit-2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.
Laurus Labs has announced that the USFDA completed inspection of the formulations manufacturing facility Unit-2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
The Survey highlighted that Indian pharmaceutical exports achieved a healthy growth of 24 per cent in FY21 and expressed hope that India’s domestic pharmaceutical market is estimated to grow to US $65 billion by 2024 from estimated US $41 billion in 2021
It will help upgrade the infrastructure and technologies of the country's biopharmaceuticals and in-vitro diagnostic industry
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
It ensures sufficient serum estradiol levels to alleviate menopausal symptoms
There have been reports from Uzbekistan concerning contaminated cough syrup Dok1 Max made by Indian company Marion Biotech, Noida, Uttar Pradesh
Subscribe To Our Newsletter & Stay Updated